ML 03

Drug Profile

ML 03

Alternative Names: HP 3

Latest Information Update: 08 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Milkhaus Laboratory
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bronchitis; Chronic obstructive pulmonary disease; Cystic fibrosis; Respiratory tract disorders

Most Recent Events

  • 26 Jul 2001 HP 3 is now called ML 03
  • 26 Jul 2001 ML 03 is available for licensing (
  • 26 Jul 2001 Investigation in Respiratory tract disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top